CD8A and neoplasm: Sequential administration of αCTLA−4mAb to RT/αCD40mAb combination therapy was able to reverse these potentially immunosuppressive signals, and resulted in an increase in both intra-tumoral CD8 T cells and the CD8: T-reg ratio, leading to durable long-term tumor control.